SCHEMBL3556090

SCHEMBL3556090

FC1CN(c2coc3ccccc23)CCN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTR2C P28335 1/20 0.38
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
PHGDH O43175 1/20 0.35
PRKDC P78527 2/20 0.34
HTR6 P50406 3/20 0.33
SLC6A4 P31645 2/20 0.33
DRD2 P14416 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33
RPS6KB1 P23443 1/20 0.33
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560946 0.77 HTR6 (0.53) ALDH1A1KDM4EHTR6HTR3EHTR3B
SCHEMBL28241794 0.72 ALDH1A1 (0.57) ALDH1A1KDM4ECHRNB2CHRNA4CHRM2
SCHEMBL4423739 0.71 ADRB1 (0.52) ALDH1A1KDM4EHTR3EHTR3BHTR1A
SCHEMBL11321507 0.71 ALDH1A1 (0.57) ALDH1A1KDM4ECHRNB2CHRNA4CHRM2
SCHEMBL11872695 0.70 ALDH1A1 (0.49) ALDH1A1KDM4ECHRNB2CHRNA4CHRM2
SCHEMBL28569134 0.70 PIM1 (0.37) ALDH1A1HTR2CSLC6A4SLC6A2SLC6A3
SCHEMBL24524524 0.69 KDM4E (0.77) ALDH1A1KDM4ECHRNB2CHRNA4PHGDH
SCHEMBL3588307 0.68 ALDH1A1 (0.53) ALDH1A1KDM4ECHRNB2CHRNA4PHGDH
SCHEMBL31358115 0.67 ALDH1A1 (0.41) ALDH1A1KDM4ECHRNB2CHRNA4CHRM2
SCHEMBL28194684 0.67 KDM4E (0.71) ALDH1A1KDM4EHTR6HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671056-B2 Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor WYETH LLC (US) 2010-03-02 US disclosed
EP-1888559-A2 PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR Wyeth a Corporation of the State of Delaware (US) 2008-02-20 EP disclosed
US-20070027160-A1 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction WYETH (US) 2007-02-01 US disclosed
WO-2006135839-A2 PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR WYETH (US) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027160-A1 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction HTR5A, HTR2C, HTR1D ALDH1A1 752/4885KDM4E 907/4885HTR2C 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.